癌症免疫疗法的原发性、适应性和获得性耐药性。
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
作者信息
Sharma Padmanee, Hu-Lieskovan Siwen, Wargo Jennifer A, Ribas Antoni
机构信息
Department of Genitourinary Medical Oncology and Immunology,The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.
出版信息
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
Abstract
Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion. As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.
摘要
癌症免疫疗法可在患有多种组织学类型转移性癌症的患者中诱导持久反应。扩大这些治疗方法的临床适用性需要更好地理解限制癌症免疫疗法的机制。免疫系统与癌细胞之间的相互作用是持续的、动态的，并且从癌细胞的最初形成到转移性疾病的发展不断演变，而转移性疾病的发展依赖于免疫逃逸。随着免疫疗法耐药分子机制的阐明，可以推导出预防或治疗这些机制的可行策略，以改善患者的临床结局。
相似文献
1
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
2
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164. doi: 10.1200/EDBK_240837. Epub 2019 May 17.
3
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Oncologist. 2018 Apr;23(4):410-421. doi: 10.1634/theoncologist.2017-0354. Epub 2017 Dec 14.
4
Mechanisms of tumor evasion from the immune response.
Cancer Chemother Biol Response Modif. 2003;21:351-64. doi: 10.1016/s0921-4410(03)21018-8.
5
Emerging Opportunities and Challenges in Cancer Immunotherapy.
Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049.
6
Immune checkpoint modulation: rational design of combination strategies.
Pharmacol Ther. 2015 Jun;150:23-32. doi: 10.1016/j.pharmthera.2015.01.003. Epub 2015 Jan 10.
7
Strategies of tumor immune evasion.
BioDrugs. 2005;19(6):347-54. doi: 10.2165/00063030-200519060-00002.
8
Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future.
Expert Opin Investig Drugs. 2018 Jul;27(7):569-572. doi: 10.1080/13543784.2018.1494724. Epub 2018 Jul 6.
9
Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy.
Immunol Cell Biol. 2015 Apr;93(4):323-5. doi: 10.1038/icb.2015.12. Epub 2015 Feb 17.
10
[Role of T cells in tumor immunology and immunotherapy].
Magy Onkol. 2019 Sep 18;63(3):165-171. Epub 2018 Oct 24.
引用本文的文献
1
Utility of [Tc]Tc-tilmanocept, an immunosuppressive macrophage functional imaging agent in melanoma patients receiving checkpoint inhibitor treatment: a feasibility study.
Cancer Immunol Immunother. 2025 Sep 6;74(10):298. doi: 10.1007/s00262-025-04127-8.
2
Integrative bulk and single-cell transcriptomic analysis identifies a migrasome-associated lncRNA signature predictive of prognosis and immune landscape in clear cell renal cell carcinoma.
Front Immunol. 2025 Aug 20;16:1638792. doi: 10.3389/fimmu.2025.1638792. eCollection 2025.
3
Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies.
Oncoimmunology. 2025 Dec;14(1):2526444. doi: 10.1080/2162402X.2025.2526444. Epub 2025 Aug 26.
4
Multidimensional insights into exosomes in hepatocellular carcinoma: from genesis to clinical application.
Front Immunol. 2025 Aug 13;16:1628573. doi: 10.3389/fimmu.2025.1628573. eCollection 2025.
5
Multifunctional Superparamagnetic Copper Iron Oxide Nanoparticles for Synergistic Cancer Therapy via Magnetic Hyperthermia, Oxidative Stress and Immune Reprogramming.
Adv Funct Mater. 2025 Mar 28. doi: 10.1002/adfm.202425286.
6
Unconventional Immunotherapies in Cancer: Opportunities and Challenges.
Pharmaceuticals (Basel). 2025 Aug 4;18(8):1154. doi: 10.3390/ph18081154.
7
Aptamers Targeting Immune Checkpoints for Tumor Immunotherapy.
Pharmaceutics. 2025 Jul 22;17(8):948. doi: 10.3390/pharmaceutics17080948.
8
Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy.
Int J Mol Sci. 2025 Aug 19;26(16):7998. doi: 10.3390/ijms26167998.
9
Immune Biomarkers for Checkpoint Blockade in Solid Tumors: Transitioning from Tissue to Peripheral Blood Monitoring and Future Integrated Strategies.
Cancers (Basel). 2025 Aug 13;17(16):2639. doi: 10.3390/cancers17162639.
10
Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics.
Cancers (Basel). 2025 Aug 11;17(16):2628. doi: 10.3390/cancers17162628.
本文引用的文献
1
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
N Engl J Med. 2016 Dec 8;375(23):2255-2262. doi: 10.1056/NEJMoa1609279.
2
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Cell. 2016 Dec 1;167(6):1540-1554.e12. doi: 10.1016/j.cell.2016.11.022.
3
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Cancer Discov. 2017 Feb;7(2):188-201. doi: 10.1158/2159-8290.CD-16-1223. Epub 2016 Nov 30.
4
Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma.
Front Oncol. 2016 Nov 9;6:236. doi: 10.3389/fonc.2016.00236. eCollection 2016.
5
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
Nature. 2016 Nov 17;539(7629):443-447. doi: 10.1038/nature20554. Epub 2016 Nov 9.
6
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
BMC Med. 2016 Oct 25;14(1):168. doi: 10.1186/s12916-016-0705-4.
7
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Cell. 2016 Oct 6;167(2):397-404.e9. doi: 10.1016/j.cell.2016.08.069. Epub 2016 Sep 22.
8
PI3Kγ is a molecular switch that controls immune suppression.
Nature. 2016 Nov 17;539(7629):437-442. doi: 10.1038/nature19834. Epub 2016 Sep 19.
9
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.
Oncoimmunology. 2015 Aug 17;5(7):e1052212. doi: 10.1080/2162402X.2015.1052212. eCollection 2016 Jul.
10
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29.
Zotero 插件